Paper Details

  1. Home
  2. Paper Details

Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis.

Author: BannCarla M, Coker-SchwimmerEmmanuel, DonahueKatrina E, GartlehnerGerald, JonasBeth L, PatelSheila V, SchulmanElizabeth R, ViswanathanMeera, WeberRachel Palmieri

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Combination therapy with tumor necrosis factor (TNF) or non-TNF biologics plus methotrexate (MTX) was more effective than MTX monotherapy in reducing disease activity and improving remission in patients with early rheumatoid arthritis (RA).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Comparative effectiveness of early rheumatoid arthritis (RA) treatments remains uncertain. PURPOSE: Compare benefits and harms of biologic drug therapies for adults with early RA within 1 year of diagnosis. DATA SOURCES: English language articles from the 2012 review to October 2017 id...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816735/

データ提供：米国国立医学図書館（NLM）

Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis

Rheumatoid arthritis (RA) is a chronic autoimmune disease that can be a real pain. This study explores the effectiveness of various treatment approaches for early RA, focusing on the combination of methotrexate (MTX) with biologic drug therapies.

The study found that combining MTX with TNF or non-TNF biologics was more effective in reducing disease activity and improving remission compared to using either MTX or a biologic alone. These findings suggest that this combination therapy might be a more potent weapon in the fight against RA.

A Powerful Combination

This study indicates that combining MTX with biologic therapies might be a more effective way to treat early RA. The researchers found that this approach led to higher rates of ACR50 response (50% improvement) than MTX monotherapy. This suggests that combining these treatments might be like combining the strength of a camel caravan with the agility of a desert fox.

A More Effective Way to Fight RA

The study sheds light on the potential benefits of combining MTX with biologic therapies for early RA. It provides evidence that this approach might offer a more effective way to manage the disease and improve patient outcomes. This discovery might be like finding a new oasis that provides a more sustainable source of water for travelers crossing the desert of RA.

Dr. Camel's Conclusion

This study offers a promising new approach to treating rheumatoid arthritis. It suggests that combining MTX with biologic therapies could provide a more effective and lasting solution for patients. The combination of these treatments might be like pairing a strong camel with a cunning desert fox, offering both power and agility in the fight against RA.

Date :
  1. Date Completed 2020-11-16
  2. Date Revised 2020-11-16
Further Info :

Pubmed ID

31388915

DOI: Digital Object Identifier

PMC6816735

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.